# CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

> **NCT03328078** · PHASE1,PHASE2 · RECRUITING · sponsor: **Curis, Inc.** · enrollment: 152 (estimated)

## Conditions studied

- Relapsed Hematologic Malignancy
- Refractory Hematologic Malignancy
- Relapsed Primary Central Nervous System Lymphoma
- Refractory Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Emavusertib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03328078
- **Lead sponsor:** Curis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-12-28
- **Primary completion:** 2026-08
- **Final completion:** 2026-10
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328078, "CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03328078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*